

Giuseppe Leone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/946258/publications.pdf>

Version: 2024-02-01

299
papers

11,970
citations

36303

51
h-index

37204

96
g-index

302
all docs

302
docs citations

302
times ranked

13859
citing authors

#	ARTICLE	IF	CITATIONS
1	Cr(III) Complexes Bearing a $\hat{\eta}^2$ -Ketoimine Ligand for Olefin Polymerization: Are There Differences between Coordinative and Covalent Bonding?. <i>Catalysts</i> , 2022, 12, 119.	3.5	1
2	Dynamically Cross-Linked Polyolefins via Hydrogen Bonds: Tough yet Soft Thermoplastic Elastomers with High Elastic Recovery. <i>ACS Applied Polymer Materials</i> , 2022, 4, 3770-3778.	4.4	8
3	Polyolefin thermoplastic elastomers from polymerization catalysis: Advantages, pitfalls and future challenges. <i>Progress in Polymer Science</i> , 2021, 113, 101342.	24.7	118
4	NEt ₃ -Triggered Synthesis of UHMWPE Using Chromium Complexes Bearing Non-innocent Iminopyridine Ligands. <i>Macromolecules</i> , 2021, 54, 1243-1253.	4.8	10
5	Some Novel Cobalt Diphenylphosphine Complexes: Synthesis, Characterization, and Behavior in the Polymerization of 1,3-Butadiene. <i>Molecules</i> , 2021, 26, 4067.	3.8	2
6	Highly Stereoregular 1,3-Butadiene and Isoprene Polymers through Monoalkyl-N-Aryl-Substituted Iminopyridine Iron Complex-Based Catalysts: Synthesis and Characterization. <i>Macromolecules</i> , 2021, 54, 9947-9959.	4.8	14
7	Vanadium-Catalyzed Terpolymerization of $\hat{\eta}^2$ -Dienes with Ethylene and Cyclic Olefins: Ready Access to Polar-Functionalized Polyolefins. <i>Macromolecules</i> , 2021, 54, 10700-10711.	4.8	7
8	Semibatch Terpolymerization of Ethylene, Propylene, and 5-Ethylidene-2-norbornene: Heterogeneous High-Ethylene EPDM Thermoplastic Elastomers. <i>Macromolecules</i> , 2020, 53, 5881-5894.	4.8	24
9	Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials. <i>Cancers</i> , 2020, 12, 3334.	3.7	6
10	Rationalizing the Effect of Triethylaluminum on the Cr/SiO ₂ -Phillips Catalysts. <i>ACS Catalysis</i> , 2020, 10, 2694-2706.	11.2	15
11	Novel Cobalt Dichloride Complexes with Hindered Diphenylphosphine Ligands: Synthesis, Characterization, and Behavior in the Polymerization of Butadiene. <i>Molecules</i> , 2019, 24, 2308.	3.8	8
12	Synthesis, chain conformation and crystal structure of poly(norbornadiene) having repeating 3,5-enchained nortricyclene units. <i>Polymer Chemistry</i> , 2019, 10, 4593-4603.	3.9	7
13	(Micro)structure, thermal behavior and mechanical properties of ethylene-propylene-1-octadecene terpolymers from chain-walking polymerization of 1-octadecene. <i>Polymer</i> , 2019, 166, 27-37.	3.8	23
14	Homo- and Copolymerization of Ethylene with Norbornene Catalyzed by Vanadium(III) Phosphine Complexes. <i>Molecules</i> , 2019, 24, 2088.	3.8	6
15	2,3-exo-Diheterotactic Dicyclopentadiene Oligomers: An X-ray Powder Diffraction Study of a Challenging Multiphase Case. <i>Chemistry of Materials</i> , 2019, 31, 6650-6664.	6.7	1
16	Copolymerization of ethylene with propylene and higher $\hat{\eta}^2$ -olefins catalyzed by (imido)vanadium dichloride complexes. <i>Polymer Chemistry</i> , 2019, 10, 6200-6216.	3.9	18
17	Synthesis and spectroscopic characterization of titanium pyridylanilido complexes as catalysts for the polymerization of 1,3-butadiene and isoprene. <i>Inorganica Chimica Acta</i> , 2019, 487, 331-338.	2.4	9
18	Synthesis, structure and behavior of vanadium(III) diphosphine complexes in the homo- and co-polymerization of ethylene with norbornene: the ligand donor strength and bite angle make the difference. <i>Journal of Organometallic Chemistry</i> , 2018, 861, 142-150.	1.8	14

#	ARTICLE	IF	CITATIONS
19	Chain-Walking Polymerization of $\hat{\pm}$ -Olefins by $\hat{\pm}$ -Diimine Ni(II) Complexes: Effect of Reducing the Steric Hindrance of <i>Ortho-</i> and <i>Para-</i> Aryl Substituents on the Catalytic Behavior, Monomer Enchainment, and Polymer Properties. <i>Macromolecules</i> , 2018, 51, 801-814.	4.8	55
20	Mechanical Properties of Isotactic 1,2-Poly(E-3-methyl-1,3-pentadiene): An Example of Rubbery Elasticity below Glass Transition Temperature. <i>Macromolecules</i> , 2018, 51, 488-496.	4.8	9
21	Concerted Electron Transfer in Iminopyridine Chromium Complexes: Ligand Effects on the Polymerization of Various (Di)olefins. <i>Organometallics</i> , 2018, 37, 4827-4840.	2.3	10
22	Synthesis and Structure of Syndiotactic Poly(3-methyl-1-butene): A Case of 3/1 Helical Conformation for Syndiotactic Polymers. <i>Macromolecules</i> , 2018, 51, 8574-8584.	4.8	5
23	Homo- and Co-Polymerization of Ethylene with Cyclic Olefins Catalyzed by Phosphine Adducts of (Imido)vanadium(IV) Complexes. <i>Organometallics</i> , 2018, 37, 3181-3195.	2.3	21
24	Perfectly Alternating Ethylene/2-Butene Copolymers by Hydrogenation of Highly Stereoregular 1,4-Poly(1,3-diene)s: Synthesis and Characterization. <i>Macromolecules</i> , 2017, 50, 754-761.	4.8	11
25	Polyolefin thermoplastic elastomers from 1-octene copolymerization with 1-decene and cyclopentene. <i>European Polymer Journal</i> , 2017, 93, 200-211.	5.4	27
26	Addition Oligomerization of Dicyclopentadiene: Reactivity of <i>Endo-</i> and <i>Exo-</i> Isomers and Postmodification. <i>Macromolecular Chemistry and Physics</i> , 2017, 218, 1600602.	2.2	15
27	Crystal Structure and Properties of Isotactic 1,2-Poly(<i>E-</i> -3-methyl-1,3-pentadiene). <i>Macromolecules</i> , 2017, 50, 5412-5424.	4.8	4
28	Isotactic and Syndiotactic Alternating Ethylene/Propylene Copolymers Obtained Through Non-Catalytic Hydrogenation of Highly Stereoregular <i>cis</i> -1,4 Poly(1,3-diene)s. <i>Molecules</i> , 2017, 22, 755.	3.8	8
29	Synthesis, Structure and 1,3-Butadiene Polymerization Behavior of Vanadium(III) Phosphine Complexes. <i>Catalysts</i> , 2017, 7, 369.	3.5	10
30	Novel Allyl Cobalt Phosphine Complexes: Synthesis, Characterization and Behavior in the Polymerization of Allene and 1,3-Dienes. <i>Catalysts</i> , 2017, 7, 381.	3.5	18
31	Polyolefin thermoplastic elastomers from 1-octene chain-walking polymerization. <i>Polymer</i> , 2016, 100, 37-44.	3.8	51
32	Vanadium(III)-catalyzed copolymerization of ethylene with norbornene: Microstructure at tetrad level and reactivity ratios. <i>Journal of Molecular Catalysis A</i> , 2016, 424, 220-231.	4.8	20
33	Four doses of unpegylated <i>versus</i> one dose of pegylated filgrastim as supportive therapy in χ CHOP $\hat{1}$ 4 for elderly patients with diffuse large \hat{c} ell lymphoma. <i>British Journal of Haematology</i> , 2015, 169, 787-794.	2.5	10
34	Structure and thermal properties of ethylene/4-methyl-1-pentene copolymers: Effect of comonomer and monomer sequence distribution. <i>European Polymer Journal</i> , 2015, 73, 423-432.	5.4	9
35	Characteristics and outcome of therapy-related myeloid neoplasms: Report from the χ talain network on secondary leukemias. <i>American Journal of Hematology</i> , 2015, 90, E80-5.	4.1	93
36	Ni(II) $\hat{\pm}$ -Diimine-Catalyzed $\hat{\pm}$ -Olefins Polymerization: Thermoplastic Elastomers of Block Copolymers. <i>Macromolecules</i> , 2015, 48, 1304-1312.	4.8	89

#	ARTICLE	IF	CITATIONS
37	Crystal Structure of Isotactic Poly((<i>R</i>)-3-methyl-1-pentene). <i>Macromolecules</i> , 2015, 48, 5251-5266.	4.8	7
38	Chirality, entropy and crystallization in polymers: isotactic poly(3-methyl-1-pentene) as an example of influence of chirality and entropy on the crystal structure. <i>CrystEngComm</i> , 2015, 17, 6006-6013.	2.6	6
39	InÂvitro cardiomyocyte differentiation of umbilical cord blood cells: crucial role for c-kit+ cells. <i>Cytotherapy</i> , 2015, 17, 1627-1637.	0.7	7
40	Poly(styrene)/oligo(fluorene)-intercalated fluoromica hybrids: synthesis, characterization and self-assembly. <i>Beilstein Journal of Nanotechnology</i> , 2014, 5, 2450-2458.	2.8	2
41	Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms. <i>Leukemia and Lymphoma</i> , 2014, 55, 2942-2944.	1.3	4
42	Extreme thrombocytosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2014, 55, 2958-2960.	1.3	7
43	A Crystalline 2,3- <i>exo</i> -Disyndiotactic Dicyclopentadiene Tetramer. <i>Crystal Growth and Design</i> , 2014, 14, 5767-5772.	3.0	11
44	The <i>BCL2L10</i> Leu21Arg variant and risk of therapy-related myeloid neoplasms and <i>de novo</i> myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2014, 55, 1538-1543.	1.3	22
45	Quantification of DAPK1 Promoter Methylation in Bone Marrow and Peripheral Blood as a Follicular Lymphoma Biomarker. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 467-476.	2.8	16
46	Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. <i>Leukemia and Lymphoma</i> , 2014, 55, 270-275.	1.3	43
47	Why methylation is not a marker predictive of response to hypomethylating agents. <i>Haematologica</i> , 2014, 99, 613-619.	3.5	61
48	Copolymerization of ethylene with $\hat{\pm}$ -olefins and cyclic olefins catalyzed by a Ti(IV) diisopropoxy complex bearing a tridentate [O $\hat{\sim}$,S,O $\hat{\sim}$]-type bis(phenolato) ligand. <i>Polymer Chemistry</i> , 2014, 5, 3412.	3.9	18
49	Ethylene-4-methyl-1-pentene copolymers of complex chain architecture using $\hat{\pm}$ -diimine Ni(II) catalysts: synthesis, ¹³ C NMR assignment and understanding the chain-walking mechanism. <i>Polymer Chemistry</i> , 2014, 5, 2065.	3.9	14
50	Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies. <i>Experimental Hematology</i> , 2014, 42, 731-733.	0.4	4
51	SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. <i>Haematologica</i> , 2014, 99, e152-e153.	3.5	16
52	Adult and cord blood endothelial progenitor cells have different gene expression profiles and immunogenic potential. <i>Blood Transfusion</i> , 2014, 12 Suppl 1, s367-74.	0.4	17
53	DNMT1-interacting RNAs block gene-specific DNA methylation. <i>Nature</i> , 2013, 503, 371-376.	27.8	446
54	Hierarchically structured, blue-emitting polymer hybrids through surface-initiated nitroxide-mediated polymerization and water templated assembly. <i>Journal of Materials Chemistry C</i> , 2013, 1, 6585.	5.5	16

#	ARTICLE	IF	CITATIONS
55	Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine. <i>Leukemia and Lymphoma</i> , 2013, 54, 1786-1787.	1.3	8
56	Poly(styrene)-graft-/rhodamine 6G-fluoromica hybrids: synthesis, characterization and photophysical properties. <i>Journal of Materials Chemistry C</i> , 2013, 1, 1450.	5.5	16
57	Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation. <i>Supportive Care in Cancer</i> , 2013, 21, 531-535.	2.2	50
58	Salivary Proteomic Analysis and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 888-892.	2.0	17
59	Twenty years of unrestricted hematopoietic stem cell collection and storage: impact of Joint Accreditation Committee International Society for Cellular Therapy Europe standards implementation on stem cell storage policy and resource utilization. <i>Cytotherapy</i> , 2013, 15, 519-521.	0.7	5
60	Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2013, 90, 345-348.	2.2	37
61	Polymerization of (E)-1,3-pentadiene and (E)-2-methyl-1,3-pentadiene with neodymium catalysts: Examination of the factors that affect the stereoselectivity. <i>Journal of Polymer Science Part A</i> , 2013, 51, 3227-3232.	2.3	6
62	Novel stereoregular cis-1,4 and trans-1,2 poly(diene)s: synthesis, characterization, and mechanistic considerations. <i>Polymer</i> , 2013, 54, 3492-3503.	3.8	16
63	High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacitidine: results of an Italian retrospective study. <i>Leukemia and Lymphoma</i> , 2013, 54, 658-661.	1.3	54
64	CHLORAMBUCIL PLUS RITUXIMAB AS FRONT-LINE THERAPY IN ELDERLY/UNFIT PATIENTS AFFECTED BY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A SINGLE-CENTRE EXPERIENCE.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013031.	1.3	14
65	Autoimmune Hemolytic Anemia With Gel-Based Immunohematology Tests. <i>American Journal of Clinical Pathology</i> , 2013, 139, 457-463.	0.7	14
66	Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients. <i>British Journal of Haematology</i> , 2013, 160, 673-679.	2.5	23
67	Small lymphocytic lymphoma in a patient with Fabry disease. <i>Leukemia and Lymphoma</i> , 2013, 54, 184-185.	1.3	6
68	Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups. <i>Haematologica</i> , 2013, 98, 1344-1352.	3.5	35
69	Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. <i>Haematologica</i> , 2013, 98, 239-246.	3.5	268
70	Iron in Hodgkin's Lymphoma. <i>Critical Reviews in Oncogenesis</i> , 2013, 18, 463-469.	0.4	5
71	Systemic granulomatous reaction secondary to treatment of bladder cancer with Bacillus Calmette-Guerin. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012040.	1.3	8
72	First case of breakthrough pneumonia due to <i>Aspergillus nomius</i> in a patient with acute myeloid leukemia. <i>Medical Mycology</i> , 2012, 50, 746-750.	0.7	9

#	ARTICLE	IF	CITATIONS
73	von Hippel-Lindau Disease and Erythrocytosis. <i>Journal of Clinical Oncology</i> , 2012, 30, e137-e139.	1.6	16
74	Combined Therapy with Sonic Hedgehog Gene Transfer and Bone Marrow-Derived Endothelial Progenitor Cells Enhances Angiogenesis and Myogenesis in the Ischemic Skeletal Muscle. <i>Journal of Vascular Research</i> , 2012, 49, 425-431.	1.4	32
75	Role of fecal calprotectin as biomarker of gastrointestinal GVHD after allogeneic stem cell transplantation. <i>Blood</i> , 2012, 120, 4443-4444.	1.4	22
76	High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2012, 87, E133.	4.1	2
77	Outcome of concurrent acute myeloid leukemia and granulocytic sarcoma: three clinical cases and a review of the literature. <i>Comparative Clinical Pathology</i> , 2012, 21, 725-730.	0.7	0
78	Thrombocytopenia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. <i>Blood</i> , 2012, 119, 2219-2227.	1.4	78
79	Outcome of therapy-related myeloid neoplasms treated with azacitidine. <i>Journal of Hematology and Oncology</i> , 2012, 5, 44.	17.0	49
80	Poor mobilizer: A retrospective study on proven and predicted incidence according to GITMO criteria. <i>Transfusion and Apheresis Science</i> , 2012, 47, 217-221.	1.0	14
81	Role of 18F-FDG PET-CT for evaluating the response to reduced-intensity conditioning allogeneic transplant in heavily pre-treated patients with chronic lymphocytic leukemia: preliminary results in nine patients. <i>Annals of Nuclear Medicine</i> , 2012, 26, 764-768.	2.2	1
82	Interleukin-6 plasma levels are modulated by a polymorphism in the <i>NF-κB1</i> gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 411-416.	1.3	36
83	Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem cell transplantation. <i>American Journal of Hematology</i> , 2012, 87, 641-642.	4.1	24
84	Living copolymerization of ethylene with 4-methyl-1-pentene by an η^2 -diimine Ni(ii)/Et ₂ AlCl catalyst: synthesis of diblock copolymers via sequential monomer addition. <i>Polymer Chemistry</i> , 2012, 3, 1987.	3.9	23
85	Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome. <i>Leukemia Research</i> , 2012, 36, 331-333.	0.8	28
86	In situ synthesis of fluorescent poly(norbornene)/oxazine-1 dye loaded fluoromica hybrids: supramolecular control over dye arrangement. <i>Journal of Materials Chemistry</i> , 2011, 21, 12901.	6.7	17
87	Endothelial progenitor cells are clonal and exhibit the JAK2V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. <i>Blood</i> , 2011, 117, 2700-2707.	1.4	111
88	Uncommon yeast infections in hematological patients: from diagnosis to treatment. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 1067-1075.	4.4	18
89	Uncommon mold infections in hematological patients: epidemiology, diagnosis and treatment. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 881-892.	4.4	11
90	Gene profiling of bone marrow- and adipose tissue-derived stromal cells: a key role of Kruppel-like factor 4 in cell fate regulation. <i>Cytotherapy</i> , 2011, 13, 329-340.	0.7	34

#	ARTICLE	IF	CITATIONS
91	In families with inherited thrombophilia the risk of venous thromboembolism is dependent on the clinical phenotype of the proband. <i>Thrombosis and Haemostasis</i> , 2011, 106, 646-654.	3.4	28
92	Therapy-related myeloid neoplasms. <i>Current Opinion in Oncology</i> , 2011, 23, 672-680.	2.4	49
93	Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2011, 154, 141-143.	2.5	6
94	Syndiospecific oligomerization and polymerization of norbornene with titanium catalysts. <i>Polymer</i> , 2011, 52, 5708-5715.	3.8	13
95	Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome. <i>Annals of Hematology</i> , 2011, 90, 59-65.	1.8	13
96	Primary plasma cell leukemia followed by testicular plasmacytoma. <i>International Journal of Hematology</i> , 2011, 93, 224-227.	1.6	7
97	JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis. <i>American Journal of Hematology</i> , 2011, 86, 526-528.	4.1	31
98	The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms: A retrospective multicentric GIMEMA experience. <i>American Journal of Hematology</i> , 2011, 86, 1007-1012.	4.1	47
99	Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience. <i>Hematological Oncology</i> , 2011, 29, 107-110.	1.7	2
100	Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine. <i>Leukemia Research</i> , 2011, 35, 465-471.	0.8	11
101	Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogeneic stem cell transplantation. <i>Leukemia Research</i> , 2011, 35, 422-423.	0.8	19
102	Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: Safety and efficacy evaluation. <i>Leukemia Research</i> , 2011, 35, 682-684.	0.8	28
103	Invasive aspergillosis in acute leukemias: old and new risk factors and epidemiological trends. <i>Medical Mycology</i> , 2011, 49, S13-S16.	0.7	13
104	The Viral Load of Epstein-Barr Virus (EBV) DNA in Peripheral Blood Predicts for Biological and Clinical Characteristics in Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2011, 17, 2885-2892.	7.0	89
105	Reply to S. Zucker. <i>Journal of Clinical Oncology</i> , 2011, 29, e43-e43.	1.6	0
106	INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011069.	1.3	24
107	SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011052.	1.3	8
108	Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. <i>American Journal of Hematology</i> , 2010, 85, 97-100.	4.1	48

#	ARTICLE	IF	CITATIONS
109	Endothelial progenitor cell trafficking in human immunodeficiency virus-infected persons. <i>Aids</i> , 2010, 24, 2443-2450.	2.2	33
110	Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. <i>Haematologica</i> , 2010, 95, 65-70.	3.5	79
111	The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the $\frac{1}{4}$ - TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. <i>Blood</i> , 2010, 116, 4894-4905.	1.4	134
112	Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. <i>Annals of Hematology</i> , 2010, 89, 141-146.	1.8	39
113	Essential thrombocythemia as underlying cause of malabsorption syndrome. <i>Annals of Hematology</i> , 2010, 89, 1067-1068.	1.8	0
114	Prospective Evaluation of Epstein-Barr Virus Reactivation After Stem Cell Transplantation: Association with Monoclonal Gammopathy. <i>Journal of Clinical Immunology</i> , 2010, 30, 894-902.	3.8	19
115	Epigenetic changes in therapy-related MDS/AML. <i>Chemico-Biological Interactions</i> , 2010, 184, 46-49.	4.0	36
116	Incidence and susceptibility to therapy-related myeloid neoplasms. <i>Chemico-Biological Interactions</i> , 2010, 184, 39-45.	4.0	85
117	The proliferative response to CpG-ODN stimulation predicts PFS, TTT and OS in patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2010, 34, 1189-1194.	0.8	26
118	Well-defined transition metal complexes with phosphorus and nitrogen ligands for 1,3-dienes polymerization. <i>Coordination Chemistry Reviews</i> , 2010, 254, 661-676.	18.8	162
119	Designed organo-layered silicates as nanoreactors for 1,3-butadiene stereospecific polymerization toward rubber nanocomposites synthesis. <i>Journal of Polymer Science Part A</i> , 2010, 48, 4473-4483.	2.3	20
120	Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: feasibility and utility (SEIFEM-2008B study). <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2013-2018.	3.0	19
121	Thrombopoietin Receptor Activation, Thrombopoietin Mimetic Drugs, and Hereditary Thrombocytosis: Remarks on Bone Marrow Fibrosis. <i>Journal of Clinical Oncology</i> , 2010, 28, e317-e318.	1.6	9
122	Low-Dose Valganciclovir as Preemptive Therapy for Cytomegalovirus Infection Occurring in Allogeneic Stem Cell Transplant Recipients. <i>Acta Haematologica</i> , 2010, 123, 230-234.	1.4	11
123	Anemia in Hodgkin's Lymphoma: The Role of Interleukin-6 and Hcpidin. <i>Journal of Clinical Oncology</i> , 2010, 28, 2538-2543.	1.6	86
124	Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. <i>Blood Cells, Molecules, and Diseases</i> , 2010, 45, 181-185.	1.4	28
125	Circulating hematopoietic progenitor cells after autologous stem cell transplant for hematological malignancies. <i>Leukemia and Lymphoma</i> , 2010, 51, 1135-1138.	1.3	0
126	Analysis of genome-wide methylation and gene expression induced by 5-aza-2-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 2275-2284.	1.3	43

#	ARTICLE	IF	CITATIONS
127	Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. <i>Haematologica</i> , 2010, 95, 644-650.	3.5	273
128	No evidence for fetal microchimerism in the skin of patients with pemphigoid gestationis. <i>European Journal of Dermatology</i> , 2010, 20, 122-123.	0.6	5
129	Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes. <i>Clinical Cancer Research</i> , 2009, 15, 5002-5007.	7.0	103
130	A Patient with Acute Myeloid Leukemia and a Solid Mass in the Colon. <i>Clinical Infectious Diseases</i> , 2009, 49, 1897-1898.	5.8	1
131	Phosphorylation of the activation loop tyrosines is required for sustained Syk signaling and growth factor-independent B-cell proliferation. <i>Cellular Signalling</i> , 2009, 21, 1187-1194.	3.6	41
132	Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2009, 84, 126-127.	4.1	28
133	Reliability of leukostasis grading score to identify patients with high-risk hyperleukocytosis. <i>American Journal of Hematology</i> , 2009, 84, 381-382.	4.1	42
134	Synthesis of Polybutadiene Nanocomposites: In situ Polymerization of 1,3-Butadiene Catalyzed by Phyllosilicate Interlayer Spacing-Confined Cobalt(II) Phosphine Complexes. <i>Macromolecular Chemistry and Physics</i> , 2009, 210, 279-286.	2.2	9
135	MTHFR Polymorphisms Involved in Vitamin B12 Deficiency Associated with Atrophic Gastritis. <i>Biochemical Genetics</i> , 2009, 47, 645-650.	1.7	6
136	Long-lived layered silicates-immobilized 2,6-bis(imino)pyridyl iron (II) catalysts for hybrid polyethylene nanocomposites by <i>in situ</i> polymerization: Effect of aryl ligand and silicate modification. <i>Journal of Polymer Science Part A</i> , 2009, 47, 548-564.	2.3	19
137	Prevalence of the <i>JAK2</i> V617F mutation in patients with unprovoked venous thromboembolism of common sites and without overt myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2009, 144, 965-967.	2.5	14
138	The mutant <i>JAK2</i> V617F allele burden in children with essential thrombocythemia. <i>British Journal of Haematology</i> , 2009, 145, 430-432.	2.5	10
139	Characterization of anti-D monoclonal antibody reagents based on their reactivity with the weak D phenotype. <i>Transfusion</i> , 2009, 49, 937-942.	1.6	4
140	Incidence and clinical impact of extended-spectrum- β -lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by <i>Escherichia coli</i> in patients with hematological malignancies. <i>Journal of Infection</i> , 2009, 58, 299-307.	3.3	144
141	Thermal behavior and pyrolysis products of modified organo-layered silicates as intermediates for <i>in situ</i> polymerization. <i>Journal of Analytical and Applied Pyrolysis</i> , 2009, 86, 74-81.	5.5	9
142	Persistence of molecular remission throughout pregnancy in CML after imatinib. <i>Leukemia Research</i> , 2009, 33, e6-e7.	0.8	10
143	Polymorphisms of detoxification and DNA repair enzymes in myelodysplastic syndromes. <i>Leukemia Research</i> , 2009, 33, 1068-1071.	0.8	23
144	Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. <i>Leukemia Research</i> , 2009, 33, 1352-1356.	0.8	31

#	ARTICLE	IF	CITATIONS
145	Vinyl-Type Addition Polymerization of Norbornene and Synthesis of Norbornene Macromonomers in the Presence of Ethylene Catalyzed by Cobalt(II)-Phosphine Complexes. <i>Macromolecules</i> , 2009, 42, 9231-9237.	4.8	21
146	Intravascular large B cell lymphoma: when lymphoma is suspected but routine diagnostic work-up is negative. <i>Leukemia and Lymphoma</i> , 2009, 50, 1900-1903.	1.3	4
147	Synthesis and Characterization of Isotactic 1,2-Poly(<i>E</i> -3-methyl-1,3-pentadiene). Some Remarks about the Influence of Monomer Structure on Polymerization Stereoselectivity. <i>Macromolecules</i> , 2009, 42, 3048-3056.	4.8	32
148	<i>cis</i> -1,4- <i>alt</i> -3,4 Polyisoprene: Synthesis and Characterization. <i>Macromolecules</i> , 2009, 42, 9263-9267.	4.8	68
149	Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. <i>Haematologica</i> , 2009, 94, 733-737.	3.5	51
150	Low incidence of secondary neoplasia after autotransplantation for lymphoproliferative disease: the role of pre-transplant therapy. <i>Clinical Transplantation</i> , 2008, 22, 191-199.	1.6	6
151	Mast cell leukemia: a report of ten cases. <i>Annals of Hematology</i> , 2008, 87, 505-508.	1.8	41
152	Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration. <i>Annals of Hematology</i> , 2008, 87, 891-898.	1.8	13
153	Advanced mast cell disease: an Italian Hematological Multicenter experience. <i>International Journal of Hematology</i> , 2008, 88, 483-488.	1.6	44
154	<i>In situ</i> polymerization of ethylene using metallocene catalysts: Effect of clay pretreatment on the properties of highly filled polyethylene nanocomposites. <i>Journal of Polymer Science Part A</i> , 2008, 46, 5390-5403.	2.3	28
155	Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. <i>International Journal of Cancer</i> , 2008, 123, 1586-1592.	5.1	50
156	Early diagnosis followed by front-line autologous peripheral blood stem cell transplantation for patients affected by POEMS syndrome. <i>Leukemia Research</i> , 2008, 32, 1309-1312.	0.8	30
157	PU.1 and CEBPA expression in acute myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 1448-1453.	0.8	16
158	ABO type does not affect platelet engraftment after autologous peripheral blood stem cell transplant in a series of 249 hematologic patients. <i>Transfusion</i> , 2008, 48, 2645-2646.	1.6	1
159	Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk?. <i>European Journal of Haematology</i> , 2008, 81, 242-243.	2.2	38
160	Desensitization to Thalidomide in a Patient with Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 176-178.	1.4	6
161	Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial. <i>International Journal of Cardiology</i> , 2008, 130, 457-462.	1.7	69
162	Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias. <i>Current Medicinal Chemistry</i> , 2008, 15, 1274-1287.	2.4	42

#	ARTICLE	IF	CITATIONS
163	M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. <i>Haematologica</i> , 2008, 93, 1025-1032.	3.5	18
164	Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. <i>Haematologica</i> , 2008, 93, 372-380.	3.5	316
165	Phosphorylated STAT5 Represents a New Possible Prognostic Marker in Hodgkin Lymphoma. <i>American Journal of Clinical Pathology</i> , 2008, 129, 472-477.	0.7	18
166	Chronic Lymphocytic Leukemia With Eyelid Involvement Responding to Alemtuzumab. <i>Journal of Clinical Oncology</i> , 2008, 26, 5299-5301.	1.6	1
167	Simultaneous double mismatched cord blood transplantation in a young patient with secondary myelodysplastic syndrome: Feasibility and complications. <i>Leukemia and Lymphoma</i> , 2008, 49, 821-823.	1.3	1
168	The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. <i>Blood</i> , 2008, 111, 846-855.	1.4	275
169	Scedosporiosis in patients with acute leukemia: a retrospective multicenter report. <i>Haematologica</i> , 2008, 93, 104-110.	3.5	34
170	The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophilia. <i>Thrombosis and Haemostasis</i> , 2008, 99, 1030-1034.	3.4	32
171	A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. <i>Haematologica</i> , 2008, 93, 1068-1071.	3.5	64
172	The JAK2 V617F mutation in patients with cerebral venous thrombosis: A rebuttal. <i>Thrombosis and Haemostasis</i> , 2008, 99, 1121.	3.4	14
173	Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 564-569.	1.3	14
174	Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. <i>Blood</i> , 2007, 109, 1401-1407.	1.4	249
175	ZAP-70 enhances B-cell receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. <i>Blood</i> , 2007, 109, 2032-2039.	1.4	162
176	Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. <i>Blood</i> , 2007, 110, 354-359.	1.4	71
177	All-trans Retinoic Acid in Association with Low Dose Cytosine Arabinoside in the Treatment of Acute Myeloid Leukemia in Elderly Patients. <i>American Journal of Therapeutics</i> , 2007, 14, 351-355.	0.9	18
178	Therapy-related leukemia and myelodysplasia: susceptibility and incidence. <i>Haematologica</i> , 2007, 92, 1389-1398.	3.5	184
179	Dasatinib restores full donor chimerism in a patient with imatinib-resistant Ph+ ALL relapsing after unrelated cord blood transplantation. <i>Leukemia and Lymphoma</i> , 2007, 48, 2054-2057.	1.3	7
180	The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. <i>Blood</i> , 2007, 110, 3384-3386.	1.4	50

#	ARTICLE	IF	CITATIONS
181	Beyond web 2.0: enabling multimodal web interactions using VoIP and Ajax. , 2007, , .		0
182	Report of a novel kindred with antithrombin heparin-binding site variant (47 Arg to His): Demand for an automated progressive antithrombin assay to detect molecular variants with low thrombotic risk. <i>Thrombosis and Haemostasis</i> , 2007, 98, 695-697.	3.4	27
183	Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC GIMEMA AML 13 study. <i>Haematologica</i> , 2007, 92, 389-396.	3.5	48
184	High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis. <i>Hepatology</i> , 2007, 45, 831-832.	7.3	14
185	Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2007, 31, 253-256.	0.8	20
186	MTHFR polymorphisms influence on outcome and toxicity in acute lymphoblastic leukemia patients. <i>Leukemia Research</i> , 2007, 31, 1669-1674.	0.8	53
187	The haematocrit and platelet target in polycythemia vera. <i>British Journal of Haematology</i> , 2007, 136, 249-259.	2.5	162
188	Usefulness of Granulocyte Colony-Stimulating Factor in Patients With a Large Anterior Wall Acute Myocardial Infarction to Prevent Left Ventricular Remodeling (The Rigenera Study). <i>American Journal of Cardiology</i> , 2007, 100, 397-403.	1.6	55
189	Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura. <i>Annals of Hematology</i> , 2007, 86, 225-226.	1.8	23
190	Parvovirus B19 Infection after Plasma Exchange for Myasthenia Gravis. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2007, 13, 34-38.	1.2	1
191	Tolerogenic dendritic cells: cytokine modulation comes of age. <i>Blood</i> , 2006, 108, 1435-1440.	1.4	462
192	Non-Invasive Detection of Fetal Rhesus D Status: A Comparison between Polymerase Chain Reaction and Flow Cytometry. <i>Fetal Diagnosis and Therapy</i> , 2006, 21, 404-409.	1.4	2
193	Endogenous G-CSF and CD34+ cell mobilization after acute myocardial infarction. <i>International Journal of Cardiology</i> , 2006, 111, 202-208.	1.7	116
194	Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10+IL-12low/neg accessory cells with dendritic-cell features. <i>Blood</i> , 2006, 108, 218-227.	1.4	226
195	Lower hemoglobin levels in human immunodeficiency virus-infected patients with a positive direct antiglobulin test (DAT): relationship with DAT strength and clinical stages. <i>Transfusion</i> , 2006, 46, 1237-1243.	1.6	12
196	The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. <i>British Journal of Haematology</i> , 2006, 135, 386-391.	2.5	185
197	Analysis of MTHFR polymorphisms and P16 methylation and their correlation with clinical biological features of multiple myeloma. <i>Annals of Hematology</i> , 2006, 85, 474-477.	1.8	17
198	Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells. <i>Experimental Hematology</i> , 2006, 34, 54-65.	0.4	25

#	ARTICLE	IF	CITATIONS
199	Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation. <i>Cancer</i> , 2006, 106, 859-866.	4.1	11
200	Prophylaxis and Treatment of Venous Thromboembolism in Individuals with Inherited Thrombophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 767-780.	2.7	31
201	Inherited Thrombophilia: Treatment during Pregnancy. <i>Fetal Diagnosis and Therapy</i> , 2006, 21, 281-286.	1.4	20
202	Acute lymphoblastic leukemia in elderly patients: clinical characteristics, treatment and outcome. <i>Aging Health</i> , 2006, 2, 123-133.	0.3	0
203	Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. <i>Blood</i> , 2005, 105, 4820-4827.	1.4	221
204	Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. <i>Blood</i> , 2005, 106, 27-34.	1.4	146
205	Detection of weak ϵ D with a fully automated solid-phase red cell adherence system. <i>Transfusion</i> , 2005, 45, 689-693.	1.6	4
206	Rituximab for pure red cell aplasia after ABO-mismatched allogeneic peripheral blood progenitor cell transplantation. <i>Transfusion</i> , 2005, 45, 643-645.	1.6	18
207	Secondary Ph+ acute lymphoblastic leukemia after temozolomide. <i>Annals of Hematology</i> , 2005, 84, 760-762.	1.8	42
208	Repeated Sequences in CASPASE-5 and FANCD2 but not NF1 Are Targets for Mutation in Microsatellite-Unstable Acute Leukemia/Myelodysplastic Syndrome. <i>Molecular Cancer Research</i> , 2005, 3, 251-260.	3.4	23
209	Glutathione S-transferase P1 Genotype and Prognosis in Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2005, 11, 2175-2179.	7.0	77
210	Regulatory T cells for immunotherapy of autoimmune diseases: from the bench to the bedside. <i>Expert Opinion on Therapeutic Patents</i> , 2005, 15, 1595-1616.	5.0	3
211	Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. <i>European Heart Journal</i> , 2005, 26, 1196-1204.	2.2	235
212	Profile of azacitidine. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 717-731.	0.2	1
213	The Treatment of Acute Lymphoblastic Leukaemia in the Elderly. <i>Leukemia and Lymphoma</i> , 2004, 45, 117-123.	1.3	18
214	Immune Recovery of Lymphocyte Subsets 6 Years after Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) for Lymphoproliferative Diseases. A Comparison between NHL, HD and MM in Group of 149 Patients. <i>Leukemia and Lymphoma</i> , 2004, 45, 2063-2070.	1.3	10
215	The Intracoelomic Route: A New Approach for in utero Human Cord Blood Stem Cell Transplantation. <i>Fetal Diagnosis and Therapy</i> , 2004, 19, 13-22.	1.4	17
216	Clinical isolation and functional characterization of cord blood CD133+ hematopoietic progenitor cells. <i>Transfusion</i> , 2004, 44, 1087-1097.	1.6	43

#	ARTICLE	IF	CITATIONS
217	Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN- γ . <i>European Journal of Immunology</i> , 2004, 34, 1291-1302.	2.9	120
218	Hormonal replacement therapy after stem cell transplantation. <i>Maturitas</i> , 2004, 49, 327-333.	2.4	33
219	Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. <i>Blood</i> , 2004, 103, 698-700.	1.4	79
220	The PRV-1 gene expression in essential thrombocythemia. <i>Blood</i> , 2004, 104, 2995-2996.	1.4	7
221	Novel Antithrombotic Agents: Indirect Synthetic Inhibitors of Factor Xa and Direct Thrombin Inhibitors. <i>Evidences from Clinical Studies. Current Medicinal Chemistry Cardiovascular and Hematological Agents</i> , 2004, 2, 311-326.	1.7	9
222	A New Biotin Derivative ¹ DOTA Conjugate as a Candidate for Pretargeted Diagnosis and Therapy of Tumors. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3170-3173.	6.4	43
223	Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. <i>Clinical Immunology</i> , 2003, 109, 89-102.	3.2	93
224	Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. <i>DNA Repair</i> , 2003, 2, 547-559.	2.8	45
225	Letter to the Editor. <i>Leukemia and Lymphoma</i> , 2003, 44, 1441-1443.	1.3	7
226	Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after bupropion treatment for smoking cessation. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 77-78.	1.0	3
227	Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. <i>Blood</i> , 2003, 102, 1232-1240.	1.4	330
228	Survival and Cell Cycle Control in Early Hematopoiesis: Role of Bcl-2, and the Cyclin Dependent Kinase Inhibitors P27 and P21. <i>Leukemia and Lymphoma</i> , 2002, 43, 51-57.	1.3	21
229	Overexpression of the Polycythemia Rubra Vera-1 Gene in Essential Thrombocythemia. <i>Journal of Clinical Oncology</i> , 2002, 20, 4249-4254.	1.6	51
230	The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia. <i>Blood</i> , 2002, 100, 714-717.	1.4	40
231	Negative prognostic value of glutathione S-transferase(GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. <i>Blood</i> , 2002, 100, 2703-2707.	1.4	110
232	Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. <i>Blood</i> , 2002, 100, 2562-2571.	1.4	142
233	Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. <i>Blood</i> , 2002, 100, 1972-1976.	1.4	91
234	Highly active antiretroviral therapy and allogeneic CD34+ peripheral blood progenitor cells transplantation in an HIV/HCV coinfecting patient with acute myeloid leukemia. <i>Experimental Hematology</i> , 2002, 30, 279-284.	0.4	36

#	ARTICLE	IF	CITATIONS
235	Kinetics of hemopoietic recovery after peripheral blood stem cell transplantation: Impact of stem cell purification and G-CSF. <i>American Journal of Hematology</i> , 2002, 69, 7-14.	4.1	0
236	Transforming growth factor- β 21 causes transcriptional activation of CD34 and preserves haematopoietic stem/progenitor cell activity. <i>British Journal of Haematology</i> , 2002, 118, 627-637.	2.5	19
237	Differential induction of P-glycoprotein and MRP by rifamycins in T lymphocytes from HIV-1/tuberculosis co-infected patients. <i>Aids</i> , 2002, 16, 1563-1565.	2.2	6
238	Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. <i>Blood</i> , 2001, 97, 1063-1069.	1.4	74
239	Acquired and inherited risk factors for splanchnic venous thrombosis. <i>Blood</i> , 2001, 97, 3314-3316.	1.4	2
240	Expression of p15 ^{ink4b} gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. <i>Blood</i> , 2001, 98, 495-497.	1.4	42
241	Molecular and clinical follow-up after stem cell transplantation for multiple myeloma. <i>Annals of Hematology</i> , 2001, 80, 90-95.	1.8	4
242	Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia. <i>British Journal of Haematology</i> , 2001, 112, 109-117.	2.5	51
243	The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. <i>British Journal of Haematology</i> , 2001, 113, 630-635.	2.5	80
244	The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population. <i>British Journal of Haematology</i> , 2001, 114, 150-154.	2.5	24
245	Peripheral blood progenitor cell collection after epirubicin, paclitaxel, and cisplatin combination chemotherapy using EPO-based cytokine regimens: a randomized comparison of G-CSF and sequential GM-/G-CSF. <i>Transfusion</i> , 2001, 41, 674-680.	1.6	11
246	Immune reconstitution after autologous selected peripheral blood progenitor cell transplantation: comparison of two CD34+ cell-selection systems. <i>Transfusion</i> , 2001, 41, 783-789.	1.6	21
247	The role of growth factor administration and T-cell recovery after peripheral blood progenitor cell transplantation in the treatment of solid tumors: results from a randomized comparison of G-CSF and GM-CSF. <i>Transfusion</i> , 2001, 41, 1577-1585.	1.6	12
248	T-cell apoptosis induced by granulocyte colony-stimulating factor is associated with retinoblastoma protein phosphorylation and reduced expression of cyclin-dependent kinase inhibitors. <i>Experimental Hematology</i> , 2001, 29, 401-415.	0.4	17
249	Immune reconstitution after autologous peripheral blood progenitor cell transplantation. <i>Experimental Hematology</i> , 2001, 29, 1503-1516.	0.4	28
250	Immune Reconstitution following Transplantation of Autologous Peripheral CD34+ Cells. <i>Acta Haematologica</i> , 2001, 105, 179-187.	1.4	4
251	HIV protease inhibitors reduce IL-2 release from normal human phytohaemagglutinin-activated T cells. <i>Aids</i> , 2001, 15, 2339-2341.	2.2	0
252	Immune reconstitution after transplantation of autologous peripheral CD34+ cells: analysis of predictive factors and comparison with unselected progenitor transplants. <i>British Journal of Haematology</i> , 2000, 108, 105-115.	2.5	68

#	ARTICLE	IF	CITATIONS
253	CD34+/CD105+ cells are enriched in primitive circulating progenitors residing in the G0 phase of the cell cycle and contain all bone marrow and cord blood CD34+/CD38low/â”precursors. British Journal of Haematology, 2000, 108, 610-620.	2.5	43
254	High cyclin-dependent kinase inhibitors in Bcl-2 and Bcl-xL -expressing CD34+ -proliferating haematopoietic progenitors. British Journal of Haematology, 2000, 110, 654-662.	2.5	16
255	Expression of cyclin-dependent kinase inhibitor p15INK4B during normal and leukemic myeloid differentiation. Experimental Hematology, 2000, 28, 519-526.	0.4	37
256	Granulocyte colony-stimulating factor perturbs lymphocyte mitochondrial function and inhibits cell cycle progression. Experimental Hematology, 2000, 28, 612-625.	0.4	32
257	Autologous Graft-Versus-Host Disease after CD34+-Purified Autologous Peripheral Blood Progenitor Cell Transplantation. Journal of Hematotherapy and Stem Cell Research, 2000, 9, 375-379.	1.8	15
258	Recombinant Human Granulocyte Colony-Stimulating Factor (rHuG-CSF): Effects on Lymphocyte Phenotype and Function. Journal of Interferon and Cytokine Research, 1999, 19, 989-994.	1.2	26
259	Idarubicin including regimens in acute myelogenous leukemia in elderly patients. Critical Reviews in Oncology/Hematology, 1999, 32, 59-68.	4.4	7
260	Prevalence of mild hyperhomocysteinaemia and association with thrombophilic genotypes (factor V Tj ETQq0 0 0 rgBT /Overlock 10 Tf 1 Journal of Haematology, 1999, 106, 564-568.	2.5	50
261	Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA Archive of Adult Acute Leukaemia. British Journal of Haematology, 1999, 106, 1037-1040.	2.5	70
262	Expansion of granulocyte colonyâ”stimulating factor/chemotherapyâ”mobilized CD34+ hematopoietic progenitors. Experimental Hematology, 1999, 27, 416-424.	0.4	18
263	The Risk of Recurrent Deep Venous Thrombosis among Heterozygous Carriers of Both Factor V Leiden and the G20210A Prothrombin Mutation. New England Journal of Medicine, 1999, 341, 801-806.	27.0	467
264	Secondary haematological neoplasm after treatment of adult acute lymphoblastic leukaemia: analysis of 1170 adult ALL patients enrolled in the GIMEMA trials. British Journal of Haematology, 1998, 100, 669-676.	2.5	12
265	Functional, phenotypic and molecular characterization of cytokine low-responding circulating CD34+ haemopoietic progenitors. British Journal of Haematology, 1998, 102, 1139-1150.	2.5	24
266	Flow cytometric detection of perforin in normal human lymphocyte subpopulations defined by expression of activation/differentiation antigens. Immunology Letters, 1998, 60, 51-55.	2.5	26
267	Generation of multinuclear tartrateâ”resistant acid phosphatase positive osteoclasts in liquid culture of purified human peripheral blood CD34 + progenitors. British Journal of Haematology, 1997, 96, 64-69.	2.5	17
268	Purified unfractionated Gâ”CSF/chemotherapy mobilized CD34 + peripheral blood progenitors and not bone marrow CD34 + progenitors undergo selective erythroid differentiation in liquid culture in the presence of erythropoietin and stem cell factor. British Journal of Haematology, 1997, 96, 55-63.	2.5	5
269	Evaluation of a new protocol for peripheral blood stem cell collection with the Fresenius AS 104 cell separator. Journal of Clinical Apheresis, 1997, 12, 82-86.	1.3	5
270	Differential sensitivity of leukemic and normal hematopoietic progenitors to the killing effect of hyperthermia and quercetin used in combination: Role of heat-shock protein-70. , 1997, 73, 75-83.		32

#	ARTICLE	IF	CITATIONS
271	Hodgkin's lymphoma in a cyclist treated with growth hormone. , 1996, 52, 65-66.		12
272	Allogeneic hemopoietic progenitor cells transplantation for late graft failure. American Journal of Hematology, 1995, 50, 320-320.	4.1	0
273	Aggressive Chemotherapy for Acute Leukemia Relapsed After Transplantation. Leukemia and Lymphoma, 1994, 15, 131-134.	1.3	1
274	Prevalence of obesity in young adults with acute lymphoblastic leukemia. International Journal of Clinical and Laboratory Research, 1994, 24, 117-119.	1.0	5
275	Lipids and lipoproteins in acute lymphoblastic leukaemia (ALL). Leukemia Research, 1994, 18, 643-644.	0.8	21
276	Trisomy 4 in acute myeloblastic and acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 1993, 65, 115-119.	1.0	8
277	Anthracycline Containing Regimens in Intermediate Grade Lymphoma. Leukemia and Lymphoma, 1993, 10, 39-41.	1.3	5
278	L-Asparaginase-Induced Coagulopathy in Acute Lymphoblastic Leukemia. Leukemia and Lymphoma, 1992, 7, 54-56.	1.3	2
279	Anthracycline Containing Regimens in Intermediate Grade Lymphoma. Leukemia and Lymphoma, 1992, 7, 22-24.	1.3	0
280	Hepato-Splenic Mycotic Abscesses in Patients with Acute Leukemia. Leukemia and Lymphoma, 1992, 7, 517-519.	1.3	1
281	Describing and interpreting 24-hour blood pressure patterns in physiologic pregnancy. American Journal of Obstetrics and Gynecology, 1992, 166, 54-60.	1.3	35
282	G-CSF and peripheral blood progenitor cells. Lancet, The, 1992, 339, 1410-1411.	13.7	14
283	The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growth. Leukemia Research, 1992, 16, 497-503.	0.8	49
284	Vasoactive intestinal peptide fluctuates in human blood with a circadian rhythm. Regulatory Peptides, 1991, 34, 141-148.	1.9	12
285	Mortality related to thrombosis in congenital antithrombin III deficiency. Lancet, The, 1991, 337, 847-848.	13.7	11
286	Factor V in cerebrospinal fluid of leukemic patients on intrathecal chemotherapy. Leukemia Research, 1991, 15, 768-769.	0.8	0
287	Acute Nonlymphoblastic Leukemia: Treatment of Elderly Patients. Leukemia and Lymphoma, 1990, 2, 243-245.	1.3	0
288	Mesenteric vein thrombosis in protein S congenital deficiency. Thrombosis Research, 1990, 57, 935-944.	1.7	12

#	ARTICLE	IF	CITATIONS
289	Association of Graves' disease and prekallikrein congenital deficiency in a patient belonging to the first CRM+ prekallikrein-deficient Italian family. <i>Thrombosis Research</i> , 1990, 60, 397-404.	1.7	25
290	Stepwise multivariate discriminant analysis (SMDA) for paired and unpaired biomedical data using microcomputers. <i>Computers in Biology and Medicine</i> , 1988, 18, 39-55.	7.0	5
291	Long-term cytogenetic effects of antineoplastic treatment in relation to secondary leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1988, 33, 201-211.	1.0	14
292	Ph ¹ -Chromosome-Positive Chronic Myelogenous Leukemia following a 1-Year "Off-Therapy" Acute Lymphoblastic Leukemia. <i>Oncology</i> , 1988, 45, 389-391.	1.9	3
293	Further characterization of a pathological isoantithrombin with no affinity for heparin (antithrombin III Roma). <i>Thrombosis Research</i> , 1987, 48, 23-30.	1.7	2
294	OKT4/OKT8 ratio and serum beta 2-microglobulin in mycosis fungoides and chronic benign dermatitis. <i>European Journal of Cancer & Clinical Oncology</i> , 1986, 22, 663-669.	0.7	2
295	T Lymphocyte Subsets and Platelet-Associated IgG in Idiopathic Thrombocytopenic Purpura: Effect of Splenectomy. <i>Acta Haematologica</i> , 1986, 75, 83-88.	1.4	2
296	Antithrombin III during High-Dose Cytosine Arabinoside Therapy with or without Asparaginase. <i>Acta Haematologica</i> , 1986, 75, 96-99.	1.4	8
297	Myelofibrosis Associated with IgG Myeloma. <i>Acta Haematologica</i> , 1982, 67, 139-140.	1.4	9
298	Megathrombocytes, Platelet Regeneration Time and Platelet-Associated IgG in Idiopathic Thrombocytopenic Purpura and in Thrombocytopenia Associated with Chronic Liver Disease. <i>Acta Haematologica</i> , 1981, 65, 40-47.	1.4	12
299	Basic considerations on treatment of increased platelet aggregation in diabetic vasculopathic patients. <i>Acta Diabetologica Latina</i> , 1974, 11, 437-445.	0.2	2